Skip to main content
SpringerLink
Log in

Soft Drugs. XX. Design, Synthesis, and Evaluation of Ultra-Short Acting Beta-Blockers

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

A new type of ultra-short acting β-blocker which might prove advantageous in treating acute arrhythmias was designed, synthesized and investigated. Based on the soft drug “inactive metabolite approach,” the inactive phenylacetic acid metabolite of both metoprolol and atenolol was reactivated by esterification with sulfur-containing aliphatic alcohols. Since the sulfur-containing moieties are labile to the ubiquitous esterases, the new compounds should be inactivated by a one step enzymatic cleavage back to the inactive phenylacetic acid derivative. Pharmacological and pharmacokinetic profiles of the new compounds were evaluated in rats and rabbits. Isoproterenol-induced tachycardia was inhibited with short-term infusion of each compound. This tachycardia blocking effect rapidly disappeared upon termination of infusion, while β-blocking activity was 2–4-fold longer after comparable doses of the short-acting β-blocker, esmolol. The rapid recovery from the β-receptor blockade is believed due to fast hydrolysis of the soft drugs in the body. This is supported from in vitro results showing the tl/2 of esmolol is about 10-fold longer than the new soft drugs in rat, rabbit, dog and human blood. Hydrolysis studies in phosphate buffered solutions indicated that the esters are labile to base-catalyzed hydrolysis. However, the relative t1/2 values measured in biological media compared to phosphate buffered solution clearly support rapid enzymatic cleavage of the soft drugs. Interestingly, one of the soft β-blockers, the sulfonyl ester derivative, showed a unique property of exhibiting good β-receptor blocking activity without significant hypotensive action.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. W. H. Frishman, J. Stormand, M. Kirschner, M. Poland, N. Klein, S. Halprin, T. H. LeJemtel, M. Kram and E. H. Sonnenblick. Labetalol Therapy in Patients With Systemic Hypertension and Angina Pectoris: Effects of Combined Alpha and Beta Adrenoceptor Blockade. Am. J. Cardiol. 48:917–928 (1981).

    Google Scholar 

  2. J. G. Gerber and A. S. Nies. Beta-Adrenergic Blocking Drugs. Annu. Rev. Med. 36:145–164 (1985).

    Google Scholar 

  3. D. G. McDevit. Adrenoceptor Blocking Drugs: Clinical Pharmacology and Therapeutic Use. Drugs 17:267–288 (1979).

    Google Scholar 

  4. D. J. Greenblatt and J. Koch-Weser. Adverse Reactions to β-Adrenergic Receptor Blocking Drugs: A Report from Boston Collaborative Drug Surveillance Program. Drugs 7:118–129 (1974).

    Google Scholar 

  5. H. M. Beumer. Adverse Effects of β-Adrenergic Receptor Blocking Drugs on Respiratory Function. Drugs 7:130–138 (1974).

    Google Scholar 

  6. W. Frishman, R. Silverman, J. Strom, U. Elkayam and E. Sonnenblick. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 4. Adverse effects. Choosing a β-adrenoceptor blocker. Am. Heart J. 98,2:256–262 (1979).

    Google Scholar 

  7. W. Frishman and R. Siverman. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 3. Adverse effects. Choosing a β-adrenoceptor blocker. Am. Heart J. 98:119–131 (1979).

    Google Scholar 

  8. V. S. Murphy and W. H. Frishman. Controlled Beta-receptor Blockade with Esmolol and Flestolol. Pharmacotherapy, 5,3:168–1821 (1988).

    Google Scholar 

  9. W. H. Frishman, V. H. Murphy, and J. A. Storm. Ultra-Short-Acting β-Adrenergic Blockers. Med. Clin. of North America, 72:359–372 (1988).

    Google Scholar 

  10. N. Bodor, Y. Oshiro, T. Loftsson, M. Katovich, and W. Caldwell. Soft Drugs VI. The Application of the Inactive Metabolite Approach for Design of Soft β-Blockers. Pharm. Res. 3:120–124 (1984).

    Google Scholar 

  11. P. J. Machin, D. N. Hurst, and J. M. Osbond. β-Adrenoceptor Activity of the Stereoisomer of the Bufuraolol Alcohol and Ketone Metabolites. J. Med. Chem. 28:1648–1651 (1985).

    Google Scholar 

  12. N. Bodor. Prodrugs versus soft drugs. In H. Bundgaard (ed). Design of Prodrugs. Elsevier, Chap. 11, p 333–353 (1985).

  13. N. Bodor. Novel Approaches to the Design of Safer Drugs: Soft Drugs and Site Specific Chemical Delivery System. In Advances in Drug Research, 13, Ed: B. Testa, Academic Press, London, 255–331 (1987).

    Google Scholar 

  14. N. Bodor, A. Elkoussi, M. Kano, and M. Khalifa. Soft Drugs. 7. Soft β-Blockers for Systemic and Ophthalmic Use. J. Med. Chem. 81:1651–1656 (1988).

    Google Scholar 

  15. N. Bodor and A. Elkoussi. Novel ‘soft’ β-blockers as potential safe antiglaucoma agents. Current Eye Research 7:369–374 (1988).

    Google Scholar 

  16. P. W. Erhardt, C. M. Woo, R. J. Gorzynski, and W. G. Anderson. Ultra-Short-Acting β-Adrenergic Blocking Agent. 1. (Aryloxy)propanolamines Containing Esters in the Nitrogen Substituent. J. Med. Chem. 25:1402–1407 (1982).

    Google Scholar 

  17. P. W. Erhardt, C. M. Woo, W. G. Anderson, and R. J. Gorzynski. Ultra-Short-Acting β-Adrenergic Blocking Agent. 2. (Aryloxy)propanolamines Containing Esters on the Aryl Function. J. Med. Chem. 25:1408–1412 (1982).

    Google Scholar 

  18. T. Loftsson, J. Kaminski, and N. Bodor. Improved Delivery through Biological Membranes IX: Kinetics and Metabolism of Hydrolysis of Methylsulfinylmethyl 2-Acetoxybenzoate and Related Aspirin Prodrugs. J. Pharm. Sci. 70,7:750–755 (1981).

    Google Scholar 

  19. T. Loftsson and N. Bodor. Improved Delivery through Biological Membranes X: Percutaneous Absorption and Metabolism of Methylsulfinylmethyl 2-Acetoxybenzoate and Related Aspirin Prodrugs. J. Pharm. Sci. 70,7:756–758 (1981).

    Google Scholar 

  20. P. Turlapaty, A. Laddu, V. S. Merphy, B. Singh, and R. Lee. Esmolol: A Titratable Short-Acting Intravenous Beta-Blocker for Acute Critical Care Settings. Am. Heart J. 114:866–885 (1987).

    Google Scholar 

  21. P. Benfield and E. M. Sorkin. Esmolol. A Preliminary Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efficacy. Drugs 33:392–412 (1987).

    Google Scholar 

  22. D. M. Angran, N. J. Schultz, and V. H. Tschida. Esmolol hydrochloride: An ultrashort-acting, β-adrenergic blocking agent. Clinical Pharmacy 5:288–303 (1986).

    Google Scholar 

  23. L. G. Wade, J. M. Gerdes, and R. P. Wirth. Protection of Carboxylic Acids as Methylthiomethyl Esters. Tet. Lett. 8:731–732 (1978).

    Google Scholar 

  24. A. Arfwidsson, K. O. Borg, K. Hoffman, and I. Skanberg. Metabolism of Metoprolol in the Rat in vitro and in vivo. Xenobiotica 6,11:697–711 (1976).

    Google Scholar 

  25. T. Loftsson, J. Kaminski, and N. Bodor. Improved Delivery through Biological Membranes VIII: Design, Synthesis, and In Vivo Testing of True Prodrugs of Aspirin. J. Pharm. Sci. 70,7:743–749 (1981).

    Google Scholar 

  26. C. Y. Quon and H. F. Stampli. Biochemical Properties of Blood Esmolol Esterase. Drug Meta. Dispo. 13,4:420–424 (1985).

    Google Scholar 

  27. N. Weiner. Norepinephrine, Epinephrine, and The Symphatomimetic Amines. In L. S. Goodman, A. G. Gilman, T. W. Rall, and F. Murad (eds). The Pharmacological Basis of Therapeutics. New York. 1990. pp 201–202.

  28. B. E. Bleski. Esmolol. Conn. Med. 51:669–671 (1987).

    Google Scholar 

  29. P. Turlapaty, A. Laddu, V. S. Murphy, B. Singh, and R. Lee. Esmolol: A Titratable Short-Acting Intravenous Beta-Blocker for Acute Critical Care Setting. Am. Heart J. 114:866–885 (1987).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Drug Discovery, J. Hillis Miller Health Center, University of Florida, Box 100497, College of Pharmacy, Gainesville, Florida, 32610

    Hee-Sun Yang, Whei-Mei Wu & Nicholas Bodor

Authors
  1. Hee-Sun Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Whei-Mei Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nicholas Bodor
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yang, HS., Wu, WM. & Bodor, N. Soft Drugs. XX. Design, Synthesis, and Evaluation of Ultra-Short Acting Beta-Blockers. Pharm Res 12, 329–336 (1995). https://doi.org/10.1023/A:1016283930696

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1016283930696

Search

Navigation